高磷血症新药Tenapanor药理作用及临床评价

Pharmacologic effects and clinical evaluation of Tenapanor,a new drug for hyperphosphatemia

Tenapanor是一种新型降磷药物,主要作用于钠/氢交换蛋白3(NHE3)起抑制作用,此外还可以通过下调磷酸钠盐协同转运蛋白(NAPI)的表达,从而降低肠道对磷的吸收。Tenapanor主要用于治疗终末期肾脏病-血液透析(ESRDHD)患者高磷血症。腹泻为本品最常见的不良反应。本文通过对Tenapanor进行文献检索,就其药理作用、药动学特性、临床评价、安全性、药物相互作用和用法用量进行综述。

Tenapanor is a novel phosphorus-low-ering drug,which mainly inhibits sodium/hydrogen exchange protein 3(NHE3),and also reduces intes-tinal phosphorus absorption by down-regulating the expression of sodium phosphate co-transporter protein(NAPI).Tenapanor is mainly used for the treatment of hyperphosphatemia in patients with end-stage renal disease-hemodialysis(ESRD-HD).Diarrhea is the most common adverse reaction to this product.This article reviews Tenapanor by per-forming a literature search on its pharmacological effects,pharmacokinetic properties,clinical evalua-tion,safety,drug interactions and dosage.